Books of Interest Targeting Protein Kinases for Cancer Therapy . By David J. Matthews and Mary E. Gerritsen Wiley , Hoboken, NJ . 2010 . xiii + 702 pp. 16.5 × 24 cm. ISBN 9780470229651 . $125.00. Biomarkers in Drug Development. A Handbook of Practice, Application, and Strategy . Edited by Michael R. Bleavins , Claudio Carini , Mallé Jurima-Romet , and Ramin Rahbari Wiley , Hoboken, NJ . 2010 . xvii + 744 pp. 16 × 24 cm. ISBN 9780470169278 . $160.00. BACE. Lead Target for Orchestrated Therapy of Alzheimer’s Disease . Edited by Varghese John Wiley , Hoboken, NJ . 2010 . xvi + 240 pp. 16 × 24 cm. ISBN 9780470293423 . $99.95. Cumulenes in Click Reactions . By Henri Ulrich Wiley , Hoboken, NJ . 2010. x + 562 pp. 17 × 25 cm. ISBN 978-0-470-77932-3 . $205.00. Chiral Recognition in the Gas Phase . Edited by Anne Zehnacker CRC Press , Boca Raton, FL . 2010 . xviii + 225 pp. 16 × 24 cm. ISBN 978-1-4200-8227-2 . $99.95.

2010 ◽  
Vol 53 (16) ◽  
pp. 6240-6240 ◽  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cancer Therapy ◽  
Drug Development ◽  
Gas Phase ◽  
Protein Kinases ◽  
Chiral Recognition ◽  
Lead Target ◽  
Click Reactions

Old Drugs with New Tricks; Paradigm in Drug Development Pipeline for Alzheimer’s Disease

2020 ◽  
Vol 20 ◽  
Author(s):  
Tanay Dalvi ◽  
Bhaskar Dewangan ◽  
Rudradip Das ◽  
Jyoti Rani ◽  
Suchita Dattatray Shinde ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Drug Development ◽  
Molecular Targets ◽  
Drug Repurposing ◽  
Phase Iii ◽  
Complex Nature ◽  
New Drug ◽  
Development Pipeline ◽  
Old Drugs

: The most common reason behind dementia is Alzheimer’s disease (AD) and it is predicted to be the third lifethreatening disease apart from stroke and cancer for the geriatric population. Till now only four drugs are available in the market for symptomatic relief. The complex nature of disease pathophysiology and lack of concrete evidences of molecular targets are the major hurdles for developing new drug to treat AD. The the rate of attrition of many advanced drugs at clinical stages, makes the de novo discovery process very expensive. Alternatively, Drug Repurposing (DR) is an attractive tool to develop drugs for AD in a less tedious and economic way. Therefore, continuous efforts are being made to develop a new drug for AD by repursing old drugs through screening and data mining. For example, the survey in the drug pipeline for Phase III clinical trials (till February 2019) which has 27 candidates, and around half of the number are drugs which have already been approved for other indications. Although in the past the drug repurposing process for AD has been reviewed in the context of disease areas, molecular targets, there is no systematic review of repurposed drugs for AD from the recent drug development pipeline (2019-2020). In this manuscript, we are reviewing the clinical candidates for AD with emphasis on their development history including molecular targets and the relevance of the target for AD.

Characterization of a sensitive mouse Aβ40 PD biomarker assay for Alzheimer's disease drug development in wild-type mice

Bioanalysis ◽  
2016 ◽  
Vol 8 (10) ◽  
pp. 1067-1075 ◽  
Author(s):  
Yanmei Lu ◽  
Kwame Hoyte ◽  
William H Montgomery ◽  
Wilman Luk ◽  
Dongping He ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Drug Development ◽  
Wild Type

scholarly journals Advances in recent patent and clinical trial drug development for Alzheimer’s disease

2014 ◽  
Vol 3 (4) ◽  
pp. 429-447 ◽  
Author(s):  
Haibin Liu ◽  
Lirong Wang ◽  
Weiwei Su ◽  
Xiang-Qun Xie
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trial ◽  
Drug Development ◽  
Trial Drug

scholarly journals The importance of care partner input in Alzheimer’s disease (AD) drug development

2020 ◽  
Vol 16 (S6) ◽  
Author(s):  
Tabassum Majid ◽  
Russ Paulsen ◽  
Leigh F. Callahan ◽  
Michele Potashman ◽  
Daniel Lee ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Drug Development

scholarly journals Chiral gold nanoparticles enantioselectively rescue memory deficits in a mouse model of Alzheimer’s disease

2020 ◽  
Vol 11 (1) ◽  
Author(s):  
Ke Hou ◽  
Jing Zhao ◽  
Hui Wang ◽  
Bin Li ◽  
Kexin Li ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Gold Nanoparticles ◽  
Mouse Model ◽  
Chiral Recognition ◽  
Memory Deficits ◽  
Aβ Peptides ◽  
Promising Strategy ◽  
Model Of Alzheimer’S Disease ◽  
Behavioral Impairments

Abstract Preventing aggregation of amyloid beta (Aβ) peptides is a promising strategy for the treatment of Alzheimer’s disease (AD), and gold nanoparticles have previously been explored as a potential anti-Aβ therapeutics. Here we design and prepare 3.3 nm L- and D-glutathione stabilized gold nanoparticles (denoted as L3.3 and D3.3, respectively). Both chiral nanoparticles are able to inhibit aggregation of Aβ42 and cross the blood-brain barrier (BBB) following intravenous administration without noticeable toxicity. D3.3 possesses a larger binding affinity to Aβ42 and higher brain biodistribution compared with its enantiomer L3.3, giving rise to stronger inhibition of Aβ42 fibrillation and better rescue of behavioral impairments in AD model mice. This conjugation of a small nanoparticle with chiral recognition moiety provides a potential therapeutic approach for AD.

Tau protein kinases: Involvement in Alzheimer's disease

2013 ◽  
Vol 12 (1) ◽  
pp. 289-309 ◽  
Author(s):  
Ludovic Martin ◽  
Xenia Latypova ◽  
Cornelia M. Wilson ◽  
Amandine Magnaudeix ◽  
Marie-Laure Perrin ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Protein Kinases ◽  
Tau Protein

scholarly journals The Critical Path for Alzheimer’s Disease (CPAD): Pre‐competitive data sharing and generation of innovative high‐impact quantitative tools to support Alzheimer’s disease drug development

2020 ◽  
Vol 16 (S9) ◽  
Author(s):  
Sudhir Sivakumaran ◽  
Klaus Romero ◽  
Nathan J Hanan ◽  
Vikram Sinha ◽  
Samantha Budd Haeberlein ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Drug Development ◽  
Data Sharing ◽  
Critical Path ◽  
High Impact
Sign in / Sign up

Export Citation Format

Share Document